Containing relevant Learning Zones, guidelines, trials and news.
This guideline covers diagnosing and managing hypertension (high blood pressure), including pre-eclampsia, during pregnancy, labour and birth.
United Therapeutics Corporation announced the submission of a new drug application (NDA) to the FDA for Tyvaso DPI, a novel dry powder inhalation formulation of treprostinil, for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1 pulmonary hypertension) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3 pulmonary hypertension).
United Therapeutics Corporation announced that the BEAT clinical study of esuberaprost tablets in patients suffering from pulmonary arterial hypertension did...
The CHMP recommends Edarbi/Ipreziv (azilsartan medoxomil)from Takeda for essential hypertension.Azilsartan medoxomil blocks the angiotensin II type 1 receptors and inhibits...
View this publication digest on Rho kinase inhibitor for primary open-angle glaucoma and ocular hypertension.
The 28th scientific meeting of the European Society of Hypertension (ESH) on “Hypertension and Cardiovascular Protection”, which will be held in Barcelona, Spain on June 8-11, 2018.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA has approved Uptravi (selexipag) injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients with WHO functional class (FC) II–III, who are temporarily unable to take oral therapy.
Novartis announced that Entresto (sacubitril/valsartan) has received a new indication in China for the treatment of patients with essential hypertension, a disease affecting approximately 245 million adults in the country.
The CHMP recommends Onduarp (telmisartan plus amlodipine) from Boehringer for Essential Hypertension. The combination is FDA approved as Twynsta. The...